Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a significant decline in short interest in February. As of February 15th, there was short interest totalling 274,600 shares, a decline of 16.0% from the January 31st total of 326,800 shares. Based on an average daily trading volume, of 955,100 shares, the short-interest ratio is presently 0.3 days. Approximately 9.2% of the shares of the stock are short sold.

Hedge Funds Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. Citadel Advisors LLC boosted its position in shares of Clearmind Medicine Inc. (NASDAQ:CMND) by 115.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,158 shares of the company’s stock after buying an additional 20,429 shares during the quarter. Citadel Advisors LLC owned approximately 0.89% of Clearmind Medicine worth $53,000 as of its most recent SEC filing. 96.05% of the stock is currently owned by hedge funds and other institutional investors.

Clearmind Medicine Price Performance

Shares of NASDAQ CMND traded down $0.04 during mid-day trading on Thursday, hitting $1.12. 25,527 shares of the stock were exchanged, compared to its average volume of 1,069,485. Clearmind Medicine has a twelve month low of $0.95 and a twelve month high of $2.30. The stock’s fifty day simple moving average is $1.40 and its two-hundred day simple moving average is $1.37. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.72 and a current ratio of 1.72. The company has a market cap of $4.78 million, a P/E ratio of -0.60 and a beta of 1.04.

Clearmind Medicine (NASDAQ:CMND) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported ($0.11) earnings per share (EPS) for the quarter.

About Clearmind Medicine

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.